LCM
CTKB icon

Laurion Capital Management’s Cytek Biosciences CTKB Stock Holding History

Laurion Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.6K Buy
+22,263
New +$95K ﹤0.01% 401

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Laurion Capital Management's CTKB Position: Q2 2026 in Review

Laurion Capital Management opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 22,263 shares worth $98.6K. The stake represents ﹤0.01% of the portfolio and ranks #401 among its holdings.

155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Laurion Capital Management held 22,263 shares of Cytek Biosciences worth $98.6K as of Q2 2026.
  • Cytek Biosciences was a new Laurion Capital Management position in Q2 2026.
  • Cytek Biosciences made up ﹤0.01% of Laurion Capital Management's portfolio in Q2 2026, its #401 holding.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.